| Similar Articles |
|---|
 |
Pharmaceutical Executive
September 1, 2010 |
Pharm Exec's Ninth Annual Industry Audit Professor Bill Trombetta takes a snapshot of the "Glamour 24" companies shaping the pharma industry this year and beyond.   |
Pharmaceutical Executive
September 1, 2011 |
Pharm Exec's 10th Annual Industry Audit A survey of the landscape of pharma financials over the past year, and a look at which companies rode the wave to the top of the industry in delivering value to shareholders. |
Pharmaceutical Executive
September 1, 2014
Bill Trombetta |
13th Annual Industry Audit After a dip into negative territory in 2012, 2013 delivered a resurgence in sales revenues, but the turnaround only spotlights a larger trend: the growing divide between the big Pharmas and the more nimble players. |
Pharmaceutical Executive
June 1, 2009 |
Stealth Pharmas These noteworthy pharmas and biotechs generally fly under the radar (ergo "stealth") of the mainstream media. |
Pharmaceutical Executive
September 1, 2012
Bill Trombetta |
Pharm Exec's 11th Annual Industry Audit: Busting the Tape With pharmaceuticals are eyed as a commodity purchase, those traditional high margins are getting harder to find. Shareholder value and profits now depends on finding pockets of "good" growth, in segments with long-term potential in serving an unmet medical need, with fewer players. |
Pharmaceutical Executive
April 1, 2007
Bill Trombetta |
Stealth Pharmas Big Pharma is different from the thousands of biotechs, specialty pharmas, generics makers, and other companies that make up Stealth Pharma. Yes, they have more money. But in what other ways are they different? And can we learn anything from the way Stealth Pharma competes? |
Pharmaceutical Executive
September 1, 2006
Bill Trombetta |
Industry Audit This fifth annual report dives deep into the numbers and comes up with the pharmaceutical industry's true top performers. |
Pharmaceutical Executive
September 1, 2005
Bill Trombetta |
2005 Industry Audit Who's really on top in the pharmaceutical industry? |
CIO
June 1, 2002
Raghavan Rajaji |
Lessons in Shareholder Value To deliver real value to the business, CIOs must make all investment decisions with the company's long-term goals in mind |
Real Estate Portfolio
Jul/Aug 2001
Tom Kirtland |
Investors Can Only Value What They See If REIT shares are undervalued, it is partly because the information investors receive through corporate reports has become less relevant in terms of what is needed to make a proper assessment... |
Pharmaceutical Executive
September 1, 2012
William Looney |
The Margin Call Autumn is a good time to present our annual post on how well the industry is doing in harvesting value for shareholders. Our diverse list of 24 companies, drawn from Big Pharma to the established biotechs, presents a similarly mixed picture on returns. |
The Motley Fool
July 28, 2011
Dominguez & Esterhuizen |
Board Risk: List of Companies With Low Corporate Governance Risk Do you think these boards have shareholders' interests as a top priority? |
| Knowledge@Wharton |
Re-examining Stock Options as a Way to Compensate Executives Now that an underperforming stock market and the excesses of Enron have focused new attention on the use and abuse of stock options as a way to incentivize senior managers, what changes, if any, should companies make in their design of compensation packages? |
Pharmaceutical Executive
March 1, 2014
William Looney |
The Community Ethic Regardless of how you define it, partnership is also an institutional necessity as big Pharma adjusts to disruptive changes in the way health services are financed and delivered. |
Pharmaceutical Executive
May 1, 2012
William Looney |
Seeding Beyond the Base The pharmaceutical industry's reputation as a growth industry no one wants to pay for is more secure than ever. |
Pharmaceutical Executive
September 1, 2010
William Looney |
The Coming Second Act Reinvention takes more than a pithy redraft of the strategy plan or mission statement; money, a change in business culture, and the mindset of thousands of employees is required too. |
The Motley Fool
October 26, 2011
Alyce Lomax |
Are Special Interests Taking Over Your Companies? Shareholder democracy isn't the problem; passive investing is. I ran a search on Proxy Monitor's site for socially based shareholder resolutions filed at public companies by "special interest" activists from 2008 until the present. |
The Motley Fool
July 9, 2009
Selena Maranjian |
This Metric Can Lead You to Winners Of all the measures you can use to search for quality companies, the metric known as return on invested capital can be one of the trickiest. But it's one way to find great businesses. |
CFO
October 1, 2009 |
Giving It Away Readers write to discuss the meaning of "shareholder value" and the need for CFOs to incorporate new "hard numbers" into human-resources analytics. |
Bank Director
4th Quarter 2009
Kenneth L. Glascock |
Internal Audit: Boosting Your ROI A high-performance audit function can help the bank and board achieve its risk-adjusted goals. |
OCC Bulletin
March 17, 2003 |
Interagency Policy Statement on Internal Audit and Internal Audit Outsourcing Revised guidance on internal audit and its outsourcing |
Real Estate Portfolio
Mar/Apr 2002
Ray Milnes |
Audit Committees -- A Perspective on Utilizing Internal Audit Resources A brisk current of regulatory change is sweeping through America's corporate boardrooms aimed at strengthening the independence and effectiveness of corporate audit committees, including those of REITs and other publicly traded real estate companies... |
The Motley Fool
August 27, 2011
Dan Radovsky |
A Surprisingly Good Return on a Scary Day Take a look at two bellwethers. Coca-Cola and PepsiCo are two examples of what are thought to be solidly run, profitable companies that have paid back their investors with decent growth in value and in dividends. |
Pharmaceutical Executive
June 9, 2014
William Looney |
Pharma 50 Trends: Past, Present, and Future Finding the correct coordinates for big Pharma's endless cycle of re-positioning is just as important as a winning scientific hand. |
Pharmaceutical Executive
August 1, 2014
William Looney |
A Window on the Industry: The Emerging Pharma Leaders 2014 Pharm Exec's 2014 roster of emerging pharma leaders serves as a window on work in an industry that relies on human capital as the coinage of success. |
CFO
February 1, 2003
Alix Nyberg |
Auditor Independence: Separation Anxiety Many tax services may be "inappropriate" work for auditors to perform for their audit clients, says the SEC. |
HBS Working Knowledge
February 4, 2013
Martha Lagace |
Are the 'Big Four' Audit Firms Too Big to Fail? For over a decade, there have been articles and op-eds in the popular and business press arguing that the auditing industry, currently dominated by Deloitte & Touche, Ernst & Young, KPMG, and PwC, is a tightening oligopoly, increasingly insulated from the risks of failure. |
Chemistry World
July 28, 2014
Andy Extance |
Takeover battle pushes Allergan to cut R&D jobs Despite a quarterly sales increase it describes as its strongest ever, Botox maker Allergan is laying off 1500 staff as it seeks to fend off a hostile takeover. |
